Skip to content
    AHR
    Earnings call· Mar 2026(Q1 FY26)

    American Healthcare REIT Q1 FY26 earnings call AHR

    May 8, 2026 Source

    Executive summary

    American Healthcare REIT Q1 FY26 — Ninth Consecutive Quarter of Double-Digit Same-Store NOI Growth and Raised Full-Year Guidance

    American Healthcare REIT delivered another strong quarter, marked by sustained double-digit same-store NOI growth and a significant increase in NFFO per share, leading to raised full-year guidance. The company continues to strengthen its balance sheet and execute accretive acquisitions, leveraging strong operator relationships and off-market deal flow. The interim CEO highlighted the continuity of strategy and execution despite the CEO's ongoing health recovery.

    Highlights

    5
    • Total portfolio same-store NOI growth of 12.1% for the ninth consecutive quarter.

    • NFFO of $0.50 per diluted share, representing 31.6% growth compared to Q1 2025.

    • Net debt to annualized EBITDA improved to 3.0x as of March 31, 2026, down from 3.4x.

    • Full-year 2026 NFFO per share guidance increased to a range of $2.03 to $2.09, reflecting 20% growth over 2025.

    • Unsecured revolving credit facility capacity increased from $600 million to $800 million, with zero outstanding.

    Concerns

    3
    • CEO Dan Prosky continues to recover from a health event in February, with no definitive timeline for his reentry.

    • SHOP same-store NOI growth guidance remained unchanged despite Q1 outperformance, due to strong sequential Q2 2025 performance.

    • The Medicare growth rate is decelerating, with a 2.4% proposed rate, though Trilogy manages to outperform.

    Guidance & targets

    6
    CategoryTargetConfidence
    Full-year 2026 Same-Store NOI Growth
    9% to 12%
    high materiality
    High
    Full-year 2026 Trilogy Same-Store NOI Growth
    11% to 15%
    medium materiality
    High
    Full-year 2026 SHOP Same-Store NOI Growth
    15% to 19%
    medium materiality
    High
    Full-year 2026 Outpatient Medical Same-Store NOI Growth
    0% to 2%
    low materiality
    Medium
    Full-year 2026 Triple Net Lease Same-Store NOI Growth
    2% to 3%
    low materiality
    Medium
    Full-year 2026 NFFO per Share
    $2.03 to $2.09
    high materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Total Portfolio
    Ninth consecutive quarter of double-digit total portfolio same-store NOI growth.
    Same-store NOI growth: 12.1%
    12.1%
    ISHC (Trilogy)
    NOI margins eclipsed 20% for the first time since COVID. Driven by rate and occupancy improvements and quality mix shift.
    Same-store NOI growth: 14.5%Same-store occupancy (average): 91.2%Same-store occupancy YoY increase: 220 bpsSame-store revenue growth: 6.9%Quality mix of resident days: 75.5%Quality mix YoY increase: 60 bpsSkilled nursing rate growth: 5% a yearMedicare Advantage rate growth: 6.6% (last quarter)
    14.5%>20%
    SHOP
    Performance reflects bottom-line optimization through dynamic revenue and expense management. Referral fees reduced by over 20% YoY.
    Same-store NOI growth: 19.7%Same-store occupancy (average): 88.6%Same-store occupancy YoY increase: 255 bpsSame-store NOI margin expansion: 215 bps
    19.7%20.6%

    Operational metrics

    12
    NFFO per diluted share
    $0.5031.6% growth YoY
    Q1 FY26

    Compared to $0.38 per diluted share in Q1 2025.

    Net debt to annualized EBITDA
    3.0xdown from 3.4x
    as of March 31, 2026

    Improved from 3.4x at the end of 2025 due to strong EBITDA growth.

    ATM shares sold
    8.1 million
    Q1 FY26 and early Q2 FY26

    Sold under the ATM program via forward sale agreements.

    ATM gross proceeds
    $412.7 million
    Q1 FY26 and early Q2 FY26

    Gross proceeds from ATM shares sold.

    Unsettled forward ATM agreements
    $527.4 million
    as of May 8, 2026

    Assuming full physical settlement.

    Unsecured revolving credit facility capacity
    $800 millionincreased from $600 million
    as of May 8, 2026

    Increased and extended maturity, with zero amounts outstanding.

    Revolver outstanding
    $0
    as of May 8, 2026

    Zero amounts outstanding on the unsecured revolving credit facility.

    Acquisitions closed year-to-date
    $249.2 million
    YTD FY26

    All acquisitions closed year-to-date were within the SHOP segment.

    Referral fees reduction
    >20%
    YoY

    Reduction in referral fees in the SHOP portfolio year-over-year, contributing to NOI optimization.

    Cap rate movement
    25 to 50 bps
    over last year

    General movement in cap rates over the last year, though deal-specific.

    Stabilized yields on acquisitions
    7s
    current

    Stabilized yields on current acquisitions, reflecting disciplined underwriting.

    G&A increase driver
    Q1 FY26

    Primarily tied to stock-based compensation, including operator incentive grants and the increase in stock price.

    Industry KPIs

    7
    MetricValueDetails
    Exppor growth
    Revpor growth5% a year%
    Senior housing occupancy91.2%%
    Revpor minus exppor spread
    Operator tenant concentration
    Same store noi growth by segment12.1%%
    Investment volume and sourcing mix$249.2 millionUSD

    Orderbook & backlog

    2
    Awarded deals pipeline$650 millionMay 8, 2026

    Expected to close well before the end of 2026, with a majority closing by the end of Q2 2026 and the remainder in Q3 2026.

    Development pipeline (in-process)$173.9 millionMay 8, 2026

    Expected cost, with $52.4 million funded to date. Predominantly Trilogy campus expansions and independent living villa projects.

    Deals & partnerships

    3
    Multiple (unnamed)Acquisition of 5 SHOP properties in California and Missouri$117.5 million

    Part of the $162.8 million in acquisitions closed during Q1 2026.

    Multiple (unnamed)Acquisition of 2 SHOP properties in Kansas$45.3 million

    Closed after the previous earnings call, part of the $162.8 million in acquisitions closed during Q1 2026.

    One of our trusted regional operatorsAcquisition of 6 SHOP assets in Georgia and South Carolina$86.4 million

    Closed subsequent to quarter-end, deepening Southeast presence with an existing operator.

    Capital programs

    1
    Trilogy Development Pipelineunderway$173.9 million
    Period spend: $52.4 million
    Spent to date: $52.4 million

    Benefit: Trilogy campus expansions and independent living villa projects

    Capital-efficient growth opportunities layered onto existing operational platforms, expected to extend earnings runway at attractive yields with limited market risk. Trilogy aims for 3-4 new campuses a year.

    Risks & headwinds

    3
    CEO health event and reentry timeline uncertaintyNear term

    No definitive timeline for reentry

    Mitigation: Interim CEO Jeff Hanson, with deep company knowledge, is leading day-to-day operations; CEO Dan Prosky remains engaged virtually with the Board.

    Medicare growth rate deceleration

    2.4% proposed rate

    Mitigation: Trilogy's business model includes a significant private pay component and selective Medicare Advantage partnerships, allowing them to achieve rate growth (6.6% last quarter) above the Medicare rate.

    Competitive market for SHOP assetsLast year

    Cap rates moved 25-50 bps over the last year

    Mitigation: Company leverages off-market deals (half of activity), strong operator relationships, and disciplined underwriting focused on long-term cash flow durability to find accretive opportunities below replacement cost.

    What to watch in Q2 FY26

    5

    CEO Dan Prosky's reentry timeline

    Near term
    CurrentRecovering at home, no definitive timeline
    TargetClarity on reentry timeline

    Why it matters

    CEO leadership is critical for strategic direction and investor confidence.

    Although we don't have a definitive time line for his reentry given the recent procedure, we do expect to have that clarity soon and look forward to sharing the details with you in the near term.

    Q&A highlights

    8

    Why was SHOP same-store NOI guidance unchanged despite Q1 outperformance, unlike Trilogy?

    Management explained that Trilogy's strong Q1 warranted a guidance raise, but SHOP's Q2 2025 had a significant sequential uptick (9.3% NOI increase), leading to caution in raising Q1 2026 guidance despite conviction in operators.

    If you look at the supplemental and go into the SHOP portfolio, what you'll notice is that sequentially from Q1 of 2025 to Q2 of 2025, it is a pretty significant uptick. I think we increased -- the NOI increase on the same-store pool by a little over 9.3%. So I think that's part of the reason why it gave us pause.

    asked by Farrell Granath · answered by Unknown Executive

    2 min read8 chapters

    Detailed Narrative

    01

    CEO Transition and Leadership Continuity

    Jeff Hanson, Chairman and Interim CEO, provided an update on CEO Dan Prosky's health event, noting his continued recovery and virtual engagement with the Board. Hanson emphasized his deep familiarity with the company's strategy and team, ensuring full momentum and high-level execution across core metrics despite the interim period. He expects clarity on Prosky's reentry timeline soon.

    02

    Strategic Operating Partnerships

    The company's mission is to deliver high-quality care and be a trusted capital partner for operators, which is described as the core operating logic. This approach, focusing on disciplined underwriting and structuring capital for long-term performance, is credited for the strong financial results. The company highlighted the importance of operator relationships and their consistent execution.

    03

    Market Fundamentals and Demand Tailwinds

    Long-term care demand is experiencing a significant demographic wave, with the 80-plus population growing at an accelerating rate. Concurrently, new supply growth in senior housing remains near historic lows due to unfavorable construction economics. This combination of surging demand and constrained supply creates a compelling operating environment, leading to occupancy surpassing prior high watermarks and expanding margins.

    04

    Accretive Acquisition Strategy and Pipeline

    The investment team closed $249.2 million in new SHOP acquisitions year-to-date, with $162.8 million closing in Q1. The strategy prioritizes operator relationships, off-market deals, and disciplined underwriting focused on long-term cash flow durability rather than just initial yield. The company has a pipeline of over $650 million in awarded deals, expected to close primarily by the end of Q2 and Q3 2026.

    05

    Development Pipeline and Capital Efficiency

    The in-process development pipeline totals approximately $173.9 million in expected cost, with $52.4 million funded to date. These projects are predominantly Trilogy campus expansions and independent living villa projects. Management views these as capital-efficient growth opportunities layered onto existing operational platforms, designed to extend earnings runway at attractive yields with limited market risk.

    06

    Strengthened Capital Structure and Liquidity

    American Healthcare REIT improved its net debt to annualized EBITDA to 3.0x as of March 31, 2026, down from 3.4x. The unsecured revolving credit facility capacity was increased from $600 million to $800 million, with zero amounts outstanding. The ATM program generated $412.7 million in gross proceeds from 8.1 million shares sold and has $527.4 million in unsettled forward agreements, providing ample liquidity for external growth plans.

    07

    Trilogy's Outperformance and Margin Expansion

    The ISHC (Trilogy) segment delivered 14.5% same-store NOI growth and averaged 91.2% occupancy, with NOI margins exceeding 20% for the first time since COVID. This performance was driven by continued improvement in quality mix (75.5% of resident days from quality sources) and effective management of Medicare Advantage plans, allowing for selective partnerships and rate growth.

    08

    SHOP Portfolio Optimization and Expense Management

    The SHOP segment achieved 19.7% same-store NOI growth and 88.6% average occupancy. The company employs dynamic revenue and expense management, including managing street rates and taking a measured approach to in-place pricing. Notably, referral fees in the SHOP portfolio were reduced by over 20% year-over-year, contributing to NOI optimization.

    AI-generated summary of the company’s earnings call. Not investment advice.